Tumor vessel co-option: The past & the future

Area of Science:

• Oncology
• Cancer Biology
• Vascular Biology

Background:

• Tumor vessel co-option (VCO) is a non-angiogenic mechanism where tumors hijack host blood vessels.
• VCO is implicated in resistance to anti-angiogenic therapy (AAT), a common cancer treatment.
• The molecular drivers and cellular characteristics of VCO remain poorly understood.

Purpose of the Study:

• To review current knowledge on molecular mechanisms and models of VCO.
• To highlight recent sequencing-based studies on VCO.
• To propose future applications of novel technologies for VCO research.

Main Methods:

• Literature review of VCO mechanisms and models.
• Analysis of recent studies employing sequencing technologies (e.g., single-cell RNA sequencing).
• Discussion of emerging technologies for investigating tumor vascularization.

Main Results:

• VCO enables tumors to obtain blood supply independently of sprouting angiogenesis.
• Existing research on VCO, particularly using sequencing, is emerging.
• Novel technologies offer potential to elucidate VCO complexities.

Conclusions:

• Understanding VCO is crucial for overcoming AAT resistance.
• Advanced technologies like single-cell RNA sequencing can reveal VCO-specific endothelial cell (EC) biology.
• Future research using novel methods may identify vulnerabilities in VCO-dependent tumors, leading to new therapeutic strategies.